Honrado Emiliano, Benítez Javier, Palacios José
Group of Breast and Gynecological Cancer, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
Hered Cancer Clin Pract. 2004 Jul 15;2(3):131-8. doi: 10.1186/1897-4287-2-3-131.
Several studies have demonstrated that familial breast cancers associated with BRCA1 or BRCA2 germline mutations differ in their morphological and immunohistochemical characteristics. Cancers associated with BRCA1 are poorly differentiated infiltrating ductal carcinomas (IDCs) with higher mitotic counts and pleomorphism and less tubule formation than sporadic tumours. In addition, more cases with the morphological features of typical or atypical medullary carcinoma are seen in these patients. Breast carcinomas from BRCA2 mutation carriers tend to be of higher grade than sporadic age-matched controls. Regarding immunophenotypic features. BRCA1 tumours have been found to be more frequently oestrogen receptor- (ER) and progesterone receptor-(PR) negative, and p53-positive than age-matched controls, whereas these differences are not usually found in BRCA2-associated tumours. A higher frequency and unusual location of p53 mutations have been described in BRCA1/2 carcinomas. Furthermore, BRCA1- and BRCA2-associated breast carcinomas show a low frequency of HER-2 expression. Recent studies have shown that most BRCA1 carcinomas belong to the basal cell phenotype, a subtype of high grade, highly proliferating ER/HER2-negative breast carcinoma characterized by the expression of basal or myoepithelial markers, such as basal keratins, P-cadherin, EGFR, etc. This phenotype occurs with a higher incidence in BRCA1 tumours than in sporadic carcinomas and is rarely found in BRCA2 carcinomas. Hereditary carcinomas not attributable to BRCA1/2 mutations have phenotypic similarities with BRCA2 tumours, but tend to be of lesser grade and lower proliferation index. The pathological features of hereditary breast cancer can drive specific treatment and influence the process of mutation screening.
多项研究表明,与BRCA1或BRCA2种系突变相关的家族性乳腺癌在形态学和免疫组化特征上存在差异。与BRCA1相关的癌症是低分化浸润性导管癌(IDC),与散发性肿瘤相比,其有丝分裂计数更高、细胞多形性更明显且小管形成更少。此外,这些患者中出现典型或非典型髓样癌形态特征的病例更多。BRCA2突变携带者的乳腺癌往往比年龄匹配的散发性对照病例分级更高。关于免疫表型特征,已发现BRCA1肿瘤比年龄匹配的对照病例更频繁地出现雌激素受体(ER)和孕激素受体(PR)阴性以及p53阳性,而这些差异在BRCA2相关肿瘤中通常不存在。在BRCA1/2癌中已描述了p53突变的较高频率和异常位置。此外,BRCA1和BRCA2相关的乳腺癌HER-2表达频率较低。最近的研究表明,大多数BRCA1癌属于基底细胞表型,这是一种高级别、高增殖性的ER/HER2阴性乳腺癌亚型,其特征是表达基底或肌上皮标志物,如基底角蛋白、P-钙黏蛋白、表皮生长因子受体等。这种表型在BRCA1肿瘤中的发生率高于散发性癌,而在BRCA2癌中很少见。不归因于BRCA1/2突变的遗传性癌与BRCA2肿瘤具有表型相似性,但分级往往较低且增殖指数较低。遗传性乳腺癌的病理特征可推动特定治疗并影响突变筛查过程。